These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 12460610)

  • 1. Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Tillerson JL; Caudle WM; Reverón ME; Miller GW
    Exp Neurol; 2002 Nov; 178(1):80-90. PubMed ID: 12460610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Forced nonuse in unilateral parkinsonian rats exacerbates injury.
    Tillerson JL; Cohen AD; Caudle WM; Zigmond MJ; Schallert T; Miller GW
    J Neurosci; 2002 Aug; 22(15):6790-9. PubMed ID: 12151559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exercise induces behavioral recovery and attenuates neurochemical deficits in rodent models of Parkinson's disease.
    Tillerson JL; Caudle WM; Reverón ME; Miller GW
    Neuroscience; 2003; 119(3):899-911. PubMed ID: 12809709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease.
    Sconce MD; Churchill MJ; Greene RE; Meshul CK
    Neuroscience; 2015 Jul; 299():156-74. PubMed ID: 25943481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice.
    Leng A; Mura A; Hengerer B; Feldon J; Ferger B
    Behav Brain Res; 2004 Oct; 154(2):375-83. PubMed ID: 15313025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective alterations of gene expression in mice induced by MPTP.
    Xu Z; Cawthon D; McCastlain KA; Slikker W; Ali SF
    Synapse; 2005 Jan; 55(1):45-51. PubMed ID: 15499605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice.
    Gross CE; Ravenscroft P; Dovero S; Jaber M; Bioulac B; Bezard E
    J Neurochem; 2003 Mar; 84(6):1246-55. PubMed ID: 12614325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice.
    Mori A; Ohashi S; Nakai M; Moriizumi T; Mitsumoto Y
    Neurosci Res; 2005 Mar; 51(3):265-74. PubMed ID: 15710490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions.
    Murer MG; Dziewczapolski G; Menalled LB; García MC; Agid Y; Gershanik O; Raisman-Vozari R
    Ann Neurol; 1998 May; 43(5):561-75. PubMed ID: 9585350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of effect of testosterone and dihydrotestosterone compared to 17beta-oestradiol in 1-methyl-4-phenyl-1,2,3,6, tetrahydropyridine-mice.
    Ekue A; Boulanger JF; Morissette M; Di Paolo T
    J Neuroendocrinol; 2002 Sep; 14(9):731-6. PubMed ID: 12213134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Escin attenuates behavioral impairments, oxidative stress and inflammation in a chronic MPTP/probenecid mouse model of Parkinson's disease.
    Selvakumar GP; Janakiraman U; Essa MM; Justin Thenmozhi A; Manivasagam T
    Brain Res; 2014 Oct; 1585():23-36. PubMed ID: 24657313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ginkgo biloba extract (EGb 761) modulates the expression of dopamine-related genes in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
    Rojas P; Ruiz-Sánchez E; Rojas C; Ogren SO
    Neuroscience; 2012 Oct; 223():246-57. PubMed ID: 22885234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marked disparity between age-related changes in dopamine and other presynaptic dopaminergic markers in human striatum.
    Haycock JW; Becker L; Ang L; Furukawa Y; Hornykiewicz O; Kish SJ
    J Neurochem; 2003 Nov; 87(3):574-85. PubMed ID: 14535941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of (-)-sesamin on motor and memory deficits in an MPTP-lesioned mouse model of Parkinson's disease treated with l-DOPA.
    Zhao TT; Shin KS; Kim KS; Park HJ; Kim HJ; Lee KE; Lee MK
    Neuroscience; 2016 Dec; 339():644-654. PubMed ID: 27789382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration.
    Drolet RE; Behrouz B; Lookingland KJ; Goudreau JL
    Neurotoxicology; 2004 Sep; 25(5):761-9. PubMed ID: 15288507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
    Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
    Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of acute and sub-chronic L-dopa therapy on striatal L-dopa methylation and dopamine oxidation in an MPTP mouse model of Parkinsons disease.
    Smith ML; King J; Dent L; Mackey V; Muthian G; Griffin B; Charlton CG
    Life Sci; 2014 Aug; 110(1):1-7. PubMed ID: 24880075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Environmental enrichment in adulthood eliminates neuronal death in experimental Parkinsonism.
    Faherty CJ; Raviie Shepherd K; Herasimtschuk A; Smeyne RJ
    Brain Res Mol Brain Res; 2005 Mar; 134(1):170-9. PubMed ID: 15790541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice.
    Kilbourn MR; Kuszpit K; Sherman P
    Synapse; 2000 Mar; 35(4):250-5. PubMed ID: 10657034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
    Naskar A; Prabhakar V; Singh R; Dutta D; Mohanakumar KP
    J Pineal Res; 2015 Apr; 58(3):262-74. PubMed ID: 25626558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.